Kawakawa (Piper excelsum)

Kawakawa (Piper excelsum) is a traditional Māori medicinal plant containing bioactive compounds including myristicin, piperine, and flavonoids. These phenylpropanoid and alkaloid compounds may support traditional therapeutic applications, though clinical evidence remains limited.

Origin & History

Kawakawa (Piper excelsum) is a shrub native to New Zealand, traditionally used by Māori people, with leaves serving as the primary source for medicinal extracts. Extracts are commonly prepared via methanol extraction (80% methanol washes, centrifugation at 5000×g) or aqueous methods mimicking tea preparation, yielding phenylpropanoids, lignans, flavonoids, alkaloids, and amides.

Historical & Cultural Context

Kawakawa has a history of therapeutic use by Māori in Aotearoa New Zealand, commonly consumed as a beverage (tea) and incorporated into functional foods. It represents an important plant in Māori traditional medicine, though specific historical indications are not quantified in available research.

Health Benefits

• Traditional therapeutic use by Māori people (traditional evidence only)
• Contains bioavailable compounds including myristicin, piperine, and flavonoids confirmed through human metabolism studies (PMID: 38389156 - preliminary evidence)
• Phenylpropanoid and alkaloid content similar to other medicinal plants (analytical evidence only)
• Phase 1 and 2 metabolism patterns suggest general tolerability (preliminary metabolic evidence)
• No clinical therapeutic benefits established in human trials

How It Works

Kawakawa's primary bioactive compounds include myristicin, which may modulate hepatic phase II detoxification enzymes, and piperine, which can inhibit cytochrome P450 enzymes and enhance bioavailability of other compounds. The flavonoid content may contribute to antioxidant activity through free radical scavenging pathways. Phenylpropanoid compounds likely interact with inflammatory mediators, though specific receptor binding data is limited.

Scientific Research

No human clinical trials, RCTs, or meta-analyses evaluating therapeutic outcomes have been conducted. One study (PMID: 38389156) examined human metabolism and excretion of kawakawa leaf compounds after consumption, confirming bioavailability but not assessing clinical endpoints or efficacy.

Clinical Summary

Current clinical evidence for kawakawa is extremely limited, with only preliminary human metabolism studies (PMID: 38389156) confirming bioavailability of key compounds like myristicin and piperine. No randomized controlled trials have evaluated therapeutic efficacy in humans. Traditional use evidence from Māori practices spans centuries but lacks quantified outcomes or standardized preparations. Further clinical research is needed to validate traditional therapeutic claims.

Nutritional Profile

{"macronutrients": {"fiber": "Approximately 2.5g per 100g of leaves", "protein": "Approximately 3g per 100g of leaves"}, "micronutrients": {"vitamins": {"Vitamin C": "Approximately 12mg per 100g of leaves"}, "minerals": {"Calcium": "Approximately 150mg per 100g of leaves", "Potassium": "Approximately 450mg per 100g of leaves"}}, "bioactive_compounds": {"myristicin": "Concentration not specified, but bioavailable", "piperine": "Concentration not specified, but bioavailable", "flavonoids": "Concentration not specified, but bioavailable", "phenylpropanoids": "Concentration not specified", "alkaloids": "Concentration not specified"}, "bioavailability_notes": "Bioactive compounds such as myristicin, piperine, and flavonoids have been confirmed to be bioavailable through human metabolism studies."}

Preparation & Dosage

No clinically studied dosage ranges are available as human therapeutic trials have not been conducted. Traditional preparation involves aqueous extraction (tea) or concentrated extracts, but therapeutic doses have not been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Black pepper, turmeric, ginger, kava, green tea

Safety & Interactions

Safety data for kawakawa supplementation is minimal, with no established adverse effect profile in clinical literature. The piperine content may theoretically enhance absorption of medications by inhibiting cytochrome P450 enzymes, potentially altering drug metabolism. Myristicin in high concentrations has shown hepatotoxic potential in animal studies, though relevance to typical kawakawa use is unclear. Pregnancy and breastfeeding safety has not been established through clinical research.